{"id":"abd52d2871d4","type":"article","url":"https://hartvaat.nl/2020/10/13/laaggedoseerd-ticagrelor-versus-standaard-clopidogrel-bij-diabetes-farmacodynami/","title":"Laaggedoseerd ticagrelor versus standaard clopidogrel bij diabetes: farmacodynamiek","title_en":"Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS-6 Study.","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.120.048770","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.120.048770","authors":["Francesco Franchi","Fabiana Rollini","Latonya Been","Maryuri Briceno","Naji Maaliki","Mustafa Wali","Andrea Rivas","Andres M Pineda","Siva Suryadevara","Daniel Soffer","Martin M Zenni","Theodore A Bass","Dominick J Angiolillo"],"significance":5,"published":"2020-10-13","source_date":"2020-10-13","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/"],"congress":"","summary_en":"This pharmacodynamic study compared low-dose ticagrelor with standard clopidogrel in diabetic patients, evaluating a dose-reduction strategy that aims to maintain antiplatelet efficacy with a better bleeding profile.","created":"2026-07-03T10:28:49Z","updated":"2026-07-03T13:27:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Farmacodynamische en farmacokinetische vergelijking van laaggedoseerd ticagrelor versus standaard clopidogrel bij diabetespatiënten.","abstract_original":""}